Future development of our liposomes will include external functionalisation with a monoclonal antibody against a MM-specific cell surface protein such as B cell maturation protein (BCMA), for tumour-directed cell death and sparing of healthy tissues, in preparation for in vivo testing. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.